Labs / Assays & in vitro testing

NeuroProof Systems GmbH
Rostock, Germany · neuroproof.com
NeuroProof Systems GmbH is a contract research organization in Rostock, Germany focused on CNS drug screening and neurotoxicity testing. It provides pre-clinical screening services for pharmaceutical, biological, and neurotoxicity applications using neuronal cell cultures, iPSC-derived neurons, and microelectrode array-based assays.
They take quote requests by email.
What they offer
Neurotoxicity
Assesses neurotoxic threats using in vitro assays with primary neuronal cell cultures from mice, rats, and human iPSC-derived cell cultures.
Disease Models
Develops and applies in vitro disease models for CNS drug discovery using primary neuronal cell cultures and human iPSC-derived neuronal cell cultures.
Functional Phenotypic Screening
Performs phenotypic screening based on electrophysiological activity of complex neuronal cell systems.
Neuronal Maturation
Uses MEA neurochip technology to monitor and characterize maturation of primary mouse or human iPSC-derived network activity.
Target validation
Uses standard pharmacology methods to validate receptors in MEA experiments.
MEA Recording Services
Conducts compound testing with microelectrode array recordings and advanced data analysis, including concentration-response curves and substance database comparison.
Imaging
Provides automated imaging services for higher-throughput phenotypic screening.
Stem Cell Services
Supports iPSC-derived neuronal cell culture projects and neuronal stem cell culture protocol optimization.
Biologics and AAV Testing
Tests AAV constructs in disease modeling and AAV libraries as a service.
Data Analysis Services
Provides spike train analysis and other data analysis services for MEA recordings.
Glutamate Excitotoxicity Assay
Uses primary frontal cortex cultures or human iPSC-derived tri-cultures to model glutamate excitotoxicity and related neurodegenerative mechanisms.
Alzheimer’s Functional Phenotypic Disease Model
Studies early functional effects of Abeta42 on neuronal network activity and rescue by test compounds.
Parkinson's Disease In Vitro Disease Models and PD Screening Assays
Models Parkinson’s disease using agents such as MPP+, alpha-synuclein, and disease-associated mutations or patient-derived iPSC models.
What they work on
- Modalities
- Small molecule, Peptide, Viral vector, Cell therapy
- Species and models
- mouse, rat, human iPSC-derived cell cultures, primary neuronal cell cultures, primary frontal cortex cultures, primary mouse hippocampal neurons, primary mouse midbrain cultures, dopaminergic neuronal cultures, glutamatergic neurons, GABAergic neurons, astrocytes
- Assays and studies
- MEA-based phenotypic screening, spontaneous network activity recording, compound-induced network activity recording, concentration-response experiments, substance database comparison, spike train analysis, hyperexcitation pattern recognition, viability assay, apoptosis assay, oxidative stress assay, cell viability and cytotoxicity, ALS biomarker assays, and 1 more
- Instruments and platforms
- Maestro MEA System from Axion Biosystems, MEA neurochips
- Scale and capacity
- medium-throughput screening, thousands of experiments, hundreds of projects
- Therapeutic areas
- CNS drug discovery, neurotoxicity, Alzheimer's disease, Parkinson's disease, epilepsy, amyotrophic lateral sclerosis (ALS), Fragile X syndrome, schizophrenia, neuropathic pain, HIV-associated neurodegenerative disorders, Huntington's disease, autism, and 1 more
- Turnaround
- short turn around time
- Type
- CRO
- Sites
- Rostock, Germany
- Serves
- North America, Europe, Asia
Similar labs. MedChem Partners, Aurigene Pharmaceutical Services, Biofidus GmbH, Bioneeds
Found in a contract services directory. Listing built from neuroproof.com. Work here? Claim this listing.